Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
60
REGN Quote, Financials, Valuation and Earnings
Last price:
$802.92
Seasonality move
:
0.58%
Day range:
$785.00 - $806.18
52-week range:
$476.49 - $821.11
Dividend yield:
0.44%
P/E ratio:
19.32x
P/S ratio:
6.08x
P/B ratio:
2.72x
Volume:
974.8K
Avg. volume:
893.9K
1-year change:
19.12%
Market cap:
$84.9B
Revenue:
$14.3B
EPS (TTM):
$41.56
Analysts' Opinion
-
Consensus RatingRegeneron Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 17 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $868.04, Regeneron Pharmaceuticals, Inc. has an estimated upside of 8.08% from its current price of $803.17.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $730.00 representing -- downside risk from its current price of $803.17.
Fair Value
-
According to the consensus of 25 analysts, Regeneron Pharmaceuticals, Inc. has 8.08% upside to fair value with a price target of $868.04 per share.
REGN vs. S&P 500
-
Over the past 5 trading days, Regeneron Pharmaceuticals, Inc. has overperformed the S&P 500 by 1.41% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Regeneron Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Regeneron Pharmaceuticals, Inc. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Regeneron Pharmaceuticals, Inc. reported revenues of $3.9B.
Earnings Growth
-
Regeneron Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Regeneron Pharmaceuticals, Inc. reported earnings per share of $7.86.
Enterprise value:
79.3B
EV / Invested capital:
0.00x
Price / LTM sales:
6.08x
EV / EBIT:
21.41x
EV / Revenue:
5.53x
PEG ratio (5yr expected):
2.26x
EV / Free cash flow:
21.05x
Price / Operating cash flow:
23.17x
Enterprise value / EBITDA:
18.67x
Gross Profit (TTM):
$11.7B
Return On Assets:
11.59%
Net Income Margin (TTM):
31.41%
Return On Equity:
14.93%
Return On Invested Capital:
13.66%
Operating Margin:
23.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $13.1B | $14.2B | $14.3B | $3.8B | $3.9B | |
| Gross Profit | $10.9B | $11.7B | $11.7B | $3.1B | $3.2B | |
| Operating Income | $4.3B | $4.1B | $3.7B | $1B | $898.6M | |
| EBITDA | $4.7B | $4.6B | $4.2B | $1.2B | $1B | |
| Diluted EPS | $34.75 | $38.29 | $41.56 | $8.06 | $7.86 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14B | $15.9B | $19.5B | $18.7B | $18B | |
| Total Assets | $25.4B | $29.3B | $33.1B | $37.9B | $40.6B | |
| Current Liabilities | $3.9B | $3.1B | $3.4B | $3.9B | $4.4B | |
| Total Liabilities | $6.7B | $6.6B | $7.2B | $8.5B | $9.3B | |
| Total Equity | $18.8B | $22.7B | $26B | $29.4B | $31.3B | |
| Total Debt | $2.7B | $2.7B | $2.7B | $2.9B | $2.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $4.6B | $4.4B | $5B | $1.3B | $1.2B | |
| Cash From Investing | -$3.2B | -$2.5B | -$629.1M | $350.6M | $220.3M | |
| Cash From Financing | -$1.8B | -$2.2B | -$3.7B | -$1.1B | -$780.1M | |
| Free Cash Flow | $3.7B | $3.5B | $3.8B | $995.8M | $880M | |
REGN
Sector
Market Cap
$84.9B
$24M
Price % of 52-Week High
--
48.29%
Dividend Yield
0.44%
0%
Shareholder Yield
5.94%
-1.6%
1-Year Price Total Return
19.12%
-22.92%
Beta (5-Year)
0.398
0.500
Dividend yield:
0.44%
Annualized payout:
$0.00
Payout ratio:
11.2%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$778.52
200-day SMA
Buy
Level
$628.27
Bollinger Bands (100)
Buy
Level
617 - 779.86
Chaikin Money Flow
Buy
Level
448.3K
20-day SMA
Buy
Level
$762.18
Relative Strength Index (RSI14)
Buy
Level
61.64
ADX Line
Buy
Level
16.33
Williams %R
Sell
Level
-4.0311
50-day SMA
Buy
Level
$759.85
MACD (12, 26)
Buy
Level
211.73
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
2.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.5579)
Buy
CA Score
(Annual)
Level (1.3571)
Buy
Beneish M-Score
(Annual)
Level (-2.5168)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-4.368)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Stock Forecast FAQ
In the current month, REGN has received 17 Buy ratings 8 Hold ratings, and 0 Sell ratings. The REGN average analyst price target in the past 3 months is $868.04.
-
Where Will Regeneron Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Regeneron Pharmaceuticals, Inc. share price will rise to $868.04 per share over the next 12 months.
-
What Do Analysts Say About Regeneron Pharmaceuticals, Inc.?
Analysts are divided on their view about Regeneron Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Regeneron Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $730.00.
-
What Is Regeneron Pharmaceuticals, Inc.'s Price Target?
The price target for Regeneron Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $868.04 according to 25 Wall Street analysts, 17 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is REGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Regeneron Pharmaceuticals, Inc. is a Buy. 17 of 25 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of REGN?
You can purchase shares of Regeneron Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Regeneron Pharmaceuticals, Inc. shares.
-
What Is The Regeneron Pharmaceuticals, Inc. Share Price Today?
Regeneron Pharmaceuticals, Inc. was last trading at $802.92 per share. This represents the most recent stock quote for Regeneron Pharmaceuticals, Inc.. Yesterday, Regeneron Pharmaceuticals, Inc. closed at $803.17 per share.
-
How To Buy Regeneron Pharmaceuticals, Inc. Stock Online?
In order to purchase Regeneron Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get REGN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
REGN
Sector
P/E ratio
19.32x
23.25x
PEG ratio
2.26x
-0.01x
P/B ratio
2.72x
1.73x
Price / LTM sales
6.08x
1.51x
Growth Metrics
REGN
Sector
Revenue growth
2.51%
3.51%
Earnings growth
-2.57%
11.14%
Revenue (5-year growth)
11.04%
6.27%
Earnings forecast
$10.75
-$0.19
Profitability
REGN
Sector
Profitability FY 2025
$11.7B
$2.7M
Return on invested capital
13.66%
-33.58%
Return on assets
11.59%
-29.74%
Return on equity
14.93%
-38.98%
Earnings Date
Last Earnings Date
Jan
30
Next Earnings Date
Apr
29
Estimated Next Earnings Date
May
1
Balance Sheet
REGN
Sector
Total cash
$8.6B
$24.9M
Short term investments
$6.5B
$23.9M
Total assets
$40.6B
$71.6M
Long term debt
$2.9B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
